Abstract Introduction Prostate cancer (PCa) is the most commonly diagnosed cancer in men worldwide. A rising proportion of men present with de novo metastatic disease, a state associated with poor survival outcomes and limited curative treatment options. Within this group, a subset of patients exhibit oligometastatic d...
S. Lichtman-Mikol, J. Lang, H. Nagar et al.· BMJ Open· 1 citation
IMPORTANCE
Cardiovascular disease (CVD) is a leading noncancer cause of death among patients with prostate cancer (PC). Population-based risk calculators do not account for treatment-related effects of androgen-deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPis), and they have not been validated...
A. Guha, Ana Barac, M. Ryan et al.· JCO Oncology Practice· 0 citations
This cohort study evaluates rates of magnetic resonance imaging (MRI) use prior to prostate biopsy in the US from January 2017 to June 2026, as support for this practice continues to increase.
Stephen Rhodes, S. Basourakos, Jim C. Hu et al.· JAMA Oncology· 0 citations
PURPOSE
Age ≥40 years is regarded as a high-risk feature and an indication for adjuvant chemoradiotherapy for patients with lower-grade glioma in clinical practice guidelines. It is unclear whether age remains a relevant prognostic factor for contemporary definitions of lower-grade gliomas in the molecular era.
METHO...
C. Kinslow, G. Minniti, P. Brown et al.· Journal of Clinical Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.